Eunkyeong Jung
Overview
Explore the profile of Eunkyeong Jung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jung E, Foroughishafiei A, Chung Y, Steinmetz N
Small Sci
. 2024 Dec;
4(7).
PMID: 39640945
Intratumoral immunotherapies are those that are administered directly into a tumor to remodel the local tumor microenvironment and stimulate systemic anti-tumor immunity. Small molecule Toll-like receptor (TLR) agonists are undergoing...
2.
Yi S, Jung E, Kim H, Choi J, Kim S, Lim E, et al.
Small
. 2024 Oct;
21(10):e2406094.
PMID: 39422169
Extracellular vesicles (EVs) have emerged as valuable biological materials for treating intractable diseases. Extensive studies are conducted on EVs derived from various cellular sources. In this study, EVs derived from...
3.
Chung Y, Zhao Z, Jung E, Omole A, Wang H, Sutorus L, et al.
Adv Sci (Weinh)
. 2024 Mar;
11(18):e2308237.
PMID: 38430536
The key challenge in cancer treatment is prevention of metastatic disease which is therapeutically resistant and carries poor prognoses necessitating efficacious prophylactic approaches that prevent metastasis and recurrence. It is...
4.
Karan S, Jung E, Boone C, Steinmetz N
Cancer Immunol Immunother
. 2024 Feb;
73(3):51.
PMID: 38349406
Immune checkpoint therapy (ICT) for cancer can yield dramatic clinical responses; however, these may only be observed in a minority of patients. These responses can be further limited by subsequent...
5.
Shin M, Jung E, Moreno-Gonzalez M, Ortega-Rivera O, Steinmetz N
Bioeng Transl Med
. 2024 Jan;
9(1):e10574.
PMID: 38193118
Our lab demonstrated that intratumoral Cowpea mosaic virus (CPMV) is a potent antitumor immunotherapy when used as in situ vaccine. As we pave the way for human clinical translation, formulation...
6.
Chung Y, Ortega-Rivera O, Volckaert B, Jung E, Zhao Z, Steinmetz N
Proc Natl Acad Sci U S A
. 2023 Oct;
120(43):e2221859120.
PMID: 37844250
Metastatic cancer accounts for 90% of all cancer-related deaths and continues to be one of the toughest challenges in cancer treatment. A growing body of data indicates that S100A9, a...
7.
Jung E, Chung Y, Steinmetz N
Bioconjug Chem
. 2023 Aug;
34(9):1596-1605.
PMID: 37611278
Toll-like receptors (TLRs) are promising targets in cancer immunotherapy due to their role in activating the immune system; therefore, various small-molecule TLR agonists have been tested in clinical applications. However,...
8.
Jung E, Chung Y, Mao C, Fiering S, Steinmetz N
Mol Pharm
. 2023 Jun;
20(7):3589-3597.
PMID: 37294891
Plant virus nanoparticles can be used as drug carriers, imaging reagents, vaccine carriers, and immune adjuvants in the formulation of intratumoral in situ cancer vaccines. One example is the cowpea...
9.
Jung E, Kwon S, Song N, Kim N, Jo H, Yang M, et al.
Biomaterials
. 2023 Apr;
298:122127.
PMID: 37086554
Cancer cells are equipped with abundant antioxidants such as glutathione (GSH) that eliminate reactive oxygen species (ROS) to deteriorate the therapeutic efficacy of photodynamic therapy (PDT). Another challenge in PDT...
10.
Ghani M, Bangar A, Yang Y, Jung E, Sauceda C, Mandt T, et al.
J Vasc Interv Radiol
. 2023 Mar;
34(7):1247-1257.e8.
PMID: 36997021
Purpose: To test the hypothesis that cryoablation combined with intratumoral immunomodulating nanoparticles from cowpea mosaic virus (CPMV) as an in situ vaccination approach induces systemic antitumoral immunity in a murine...